Navigation Links
Medizone International Secures $10,000,000 Funding Commitment
Date:11/18/2010

SAN FRANCISCO, Nov. 18, 2010 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) (OTCQB: MZEI) announced today that it has entered into a common stock purchase agreement establishing a $10,000,000 equity line with Mammoth Corporation of Lake Zurich, IL.  The agreement is for a two-year term.  Under the terms of the agreement, Mammoth will purchase the Company's common stock at a 25% discount to the average closing bid price over a five day pricing period, with the funds transfer for the stock purchase to be made to the Company within 24 hours following the last day of the pricing period. The maximum investment limit for any one draw down of the equity line is $500,000 and there cannot be more than two draw downs during any 30-day period.  There are no options or warrants associated with this agreement. The Company determines when and how much of the investment commitment it wishes to utilize at any given time.

Edwin Marshall, CEO of Medizone, commented, "Previously, Medizone has traditionally been funded by private placements of restricted securities to accredited investors.  Until now this has served the company well as we have managed to secure the revenues needed to move forward with our projects, without having to resort to toxic financing of any kind that would cripple the company in the long term. Until we were approached by Mammoth Corporation, Medizone had never been offered a funding package by an institutional investor that we believed would truly enhance shareholder value and also ensure we had the funds available to increase our cash burn significantly when needed, which is exactly what is needed at this time in order to finalize our various research projects and enter into production with equipment suitable for a number of different market segments.  We believe that this $10,000,000 funding commitment in the form of a straight stock purchase, without warrants, options, debt funding or other toxic aspects attached, is monumental for the company and will ensure that Medizone will have the necessary financial resources to substantially complete our research, licensing, final product refinement, and to initiate production and enter a number of markets with AsepticSure™ successfully.  The financial capability and reserve created through this funding program should enhance shareholder value now and into the future while mitigating many risk factors otherwise associated with comparable financing transactions."

Brad Hare, President of Mammoth Corporation, added, "Ed and I were introduced by a trusted mutual business associate. When we realized what Medizone has achieved in the area of sterilization technology with the company's lead product AsepticSure™, it immediately became clear to me that this was a rare investment opportunity. In finalizing our due diligence, this commitment to Medizone became an easy decision.  I am not only excited about the opportunity Mammoth Corporation has relative to the anticipated financial gain from our investment, it is also wonderful to invest in something so valuable and far reaching for the good of humanity."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications.

This Press Release may contain certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues, the financial requirements of the company to achieve its business objectives, and the need for possible additional funding. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.Investor Relations:The Eversull Group, Inc.Jack Eversulljack@theeversullgroup.com972-571-1624 /(fax) 214-469-2361Web site: www.medizoneint.comE-mail: operations@medizoneint.com
'/>"/>

SOURCE Medizone International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
2. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
3. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
4. PRA International Expert to Speak at China Drug Safety Summit
5. Dyadic International Reports 2010 Third Quarter Financial Results
6. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
7. International Technidyne Corporation Acquired by Warburg Pincus
8. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
9. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
10. Dr. Fred Ueland, Markey Cancer Center, University of Kentucky Presents OVA1™ High Sensitivity Data at the 13th Annual International Gynecologic Cancer Society Meeting
11. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... SPRINGFIELD, Mass. and CAMBRIDGE, ... South Africa , Dec. 4, 2016 /PRNewswire/ ... and providing connected diagnostics software platforms for the ... on making "Anywhere. Care.™" a reality with its ... companies have entered into a development and license ...
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... Symposium (CSS) and the popularity of US Single Day Events (SDE) to organize ... early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences ...
(Date:12/2/2016)... ... ... Robots will storm the Prudential Center in Boston, MA during the ... held on the United Nations International Day of Persons with Disabilities, will highlight the ... Technologies is partnering with NTI to showcase how technology can help individuals with severe ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):